Research Progress on SMARCA4 Mutation Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2024.102.32
- VernacularTitle:SMARCA4突变非小细胞肺癌研究进展
- Author:
PENG LISHAN
1
;
ZHONG WENZHAO
Author Information
1. 510080 广州,广东省肺癌研究所,南方医科大学广东省人民医院(广东省医学科学院)
- Keywords:
Lung neoplasms;
SMARCA4;
SWI/SNF;
Immunotherapy;
Synthetic lethality
- From:
Chinese Journal of Lung Cancer
2024;27(9):704-710
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer(NSCLC)is one of the most prevalent and deadliest cancers worldwide.While the use of targeted therapies and immunotherapies in precision medicine has improved outcomes for some patients,a significant portion of individuals still fail to benefit,emphasizing the need to investigate the underlying mechanisms of resis-tance.Survival analyses have shown that NSCLC patients with SMARCA4 mutations often have poor prognoses.SMARCA4,the core ATPase subunit of the SWI/SNF chromatin remodeling complex,plays a critical role in regulating gene transcription by modifying chromatin accessibility.This influences essential cellular processes such as differentiation and cell cycle regula-tion,and SMARCA4 is widely regarded as a tumor suppressor.This review will explore the role of SMARCA4 mutations in tumor progression,its clinicopathological features in NSCLC,its impact on treatment outcomes,and potential therapeutic strategies.
